Epilepsy Surgery Market Poised for Steady Growth Driven by Advancements in Surgical Procedures and Rising Prevalence of Epilepsy.Pune, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Epilepsy Surgery Market Size & ...

Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven - MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company ...

NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

including approximately $11 million in stock-based compensation Management also outlined its long-range plan of becoming the recognized leader in drug-resistant epilepsy therapy and fully develop the ...

NeuroPace is a medical device company focused on transforming the lives of people living with epilepsy by reducing or eliminating the occurrence of debilitating seizures. Its novel and differentiated ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

NeuroPace provides the RNS System, a brain-responsive platform that delivers personalized, real-time treatment for drug-resistant epilepsy. Disclaimer: This is an AI-generated summary of a press ...

Management also outlined its long-range plan of becoming the recognized leader in drug-resistant epilepsy therapy and fully develop the potential of the RNS System. To this end, the Company is ...

including approximately $11 million in stock-based compensation Management also outlined its long-range plan of becoming the recognized leader in drug-resistant epilepsy therapy and fully develop ...